Curogen Attracts Global Investors As Novel Autoimmune, Protein Assets Progress
Curogen CEO shares what’s behind keen global investor interest in Korean venture's latest financing round and what differentiates its next-generation autoimmune disease and dermatology assets.
Scrip - March 31, 2026

Former CMS Top Official Says Brain-Computer Interface Development Outpaces CMS Coverage
Lee Fleisher, former chief medical officer at CMS, fears that lack of insurance coverage framework for implantable brain-computer interfaces could leave these technologies out of reach for patients.
Medtech Insight - March 30, 2026

Five-Minute Podcast: ‘UK Must Align More With EU’
Browne Jacobson partner Gerard Hanratty spoke at BioWales 2026 to give a legal firm’s perspective on how the UK should evolve its medtech regulatory system, pursue global harmonization and take opportunities to embed best practice AI.
Medtech Insight - March 30, 2026

Adapt To Survive: Private Hospitals In A High-Pressure Landscape
Payers' and patients' growing preference for outpatient care is increasing pressure on private providers to continually reassess how they deliver value. Jean-Philippe Grosmaitre and Guillaume Duparc, partners at L.E.K. Consulting, outlined growth opportunities available to private hospitals.
Medtech Insight - March 30, 2026

US FDA Parsing DSHEA Language For Answer: ‘Are There Any Limits’ To Dietary Substance Types?
“Are there any limits to what this category can encompass? That's the question of the day,” says ODSP director Cara Welch at public meeting to continue discussion with industry launched in 2019 about whether only ingredients found in conventional foods can be NDIs.
HBW Insight - March 31, 2026

Viatris Bets On Value-Added Medicines To Boost Growth
Viatris is accelerating its shift to higher-margin, value-added medicines, combining near-term launches, cost restructuring and disciplined dealmaking to drive sustained growth through 2030, while leveraging a stable generics base and advancing a late-stage innovative pipeline.
Generics Bulletin - March 30, 2026

Neion Bio Strikes Initial Biosimilars Deal For Its Egg-Based Platform
Announcing itself with a multi-product biosimilar deal, newly-unveiled biotech firm Neion Bio is planning to revolutionize the market with a proprietary technology platform that uses genetic engineering tools to manufacture recombinant biologics in eggs.
Generics Bulletin - March 30, 2026

Outlook Raises Cash As FDA Setbacks Cloud Future
Outlook Therapeutics has raised $23m through debt and equity financings as it continues to grapple with repeated FDA setbacks for its ophthalmic bevacizumab candidate, leaving its US approval pathway uncertain despite growing traction in Europe.
Generics Bulletin - March 30, 2026

M&A: South Korean Firms Shift To Factories Before Pipelines
South Korean pharma firms are shifting M&A focus from drug pipelines to manufacturing assets, seeking immediate production capacity and stable revenue amid high interest rates, tighter biotech financing, and global supply chain pressures.
In Vivo - March 30, 2026

BioBytes: AI-Related Deals In Q4 ‘24
The last quarter of 2024 was flush with venture financings for biotechs finding novel ways to incorporate AI into their processes.
In Vivo - March 30, 2026